Diabetic Foot Ulcer Modeling Service
Diabetic foot ulcer models serve as crucial tools for exploring the pathogenesis of diabetic foot ulcers and developing therapeutic approaches. However, establishing stable, reproducible, and highly predictive diabetic foot ulcer models remains a task fraught with technical and experiential challenges. Ace Therapeutics provides professional diabetic foot ulcer modeling services. We possess an experienced in vivo pharmacology team and well-validated in vivo models. We can recommend and customize the most suitable diabetic foot ulcer model based on clients' research objectives, delivering reliable preclinical translational tools for new drug evaluation.
Why Diabetic Foot Ulcer Modeling is Important?
Diabetic foot ulcer (DFU) healing involves the interaction of multiple cells and factors across stages, making its pathogenesis and healing process highly complex. Establishing preclinical animal models based on specific pathological foundations is crucial for in-depth mechanism research and novel drug development, with model selection tailored to scientific questions to facilitate clinical translation.
Rodents (rats and mice) are the most commonly used models, especially with gene editing technologies (e.g., db/db diabetic mouse model) enabling precise analysis of gene functions. While rodents are the essential workhorse for mechanistic and initial efficacy studies, large animal models (e.g., minipigs) are critical for specific applications, such as medical device testing, due to their closer anatomical and physiological similarity to humans.
Our Diabetic Foot Ulcer Modeling Services
Ace Therapeutics offers a range of diabetes foot ulcer models, from standard to highly customized, to meet the needs of different stages of research and development. These models have been extensively utilized in the development and evaluation of various therapeutic strategies.
| Model Name |
Strain |
Modeling Methods and Features |
Applications |
| Diabetes Full-Thickness Excision Model |
C57BL/6 mouse, SD rat |
Type 1/2 diabetes is induced via STZ or high-fat diet, followed by creation of full-thickness skin excision wounds on the back or buttocks.
Features: Mature technique, short cycle time, good reproducibility, suitable for initial screening. |
Preliminary efficacy evaluation of wound-healing drugs and dressings. |
| Diabetic Ischemic Wound Model |
C57BL/6 mouse, SD rat |
Based on induced diabetes, an ischemic environment is created by surgically ligating the blood supply arteries around the wound (such as the femoral artery and its branches). |
Evaluation of pro-angiogenic drugs and therapeutic interventions for severe ischemic ulcers. |
| Diabetic Infected Wound Model |
C57BL/6 mouse, SD rat |
Clinically relevant pathogens (e.g., Staphylococcus aureus, Pseudomonas aeruginosa) are inoculated onto full-thickness excision wounds to establish mono- or polybacterial infections.
Features: Enables quantitative assessment of a drug's antibacterial and anti-biofilm capabilities. |
Evaluation of antimicrobial agents, anti-biofilm dressings, and immunomodulators. |
| Diabetic Refractory Wound Model |
db/db mouse |
The db/db mouse model (congenital obesity and type 2 diabetes) spontaneously exhibits delayed wound healing due to genetic defects.
Features: This gold-standard model develops diabetes spontaneously without external induction, demonstrating profoundly compromised intrinsic healing capacity that amplifies drug response signals. |
Core evaluation model for advanced pro-healing therapeutics, growth factors, and cell-based therapies. |
| Large Animal Diabetic Wound Model |
Minipig |
Wounds are created at skin sites with high anatomical similarity to humans following diabetes induction via dietary or pharmacological methods.
Features: Highest translational value, especially suitable for the evaluation of medical devices (such as negative pressure therapy, skin substitutes) and topical drug delivery systems. |
Preclinical medical device validation and regulatory submission support |
Advanced Technology Platform at Ace Therapeutics
- Animal physiology monitoring platform: Blood glucose meters and HbA1c analyzers for continuous monitoring of diabetic status.
- High-resolution digital wound imaging and analysis system: Automatically and non-invasively tracking wound area changes and generating healing curves to minimize measurement variability.
- Laser doppler perfusion imager: Objectively quantifies microcirculatory blood perfusion in wound beds, providing precise assessment of ischemic model validity and drug-induced angiogenic effects.
- Microbial identification and antibiotic susceptibility testing system: Ensures accurate bacterial strain confirmation in infection models and enables correlation analysis of in vitro and in vivo drug efficacy.
- Tissue processing and histopathological analysis platform: Processes healing tissue into sections and performs staining (H&E, Masson's trichrome, immunohistochemistry, etc.) to enable in-depth, histological evaluation of healing quality.
Ace Therapeutics provides customized diabetic foot ulcer models tailored to your specific research requirements. Our experts provide complimentary, in-depth technical consultations to help you select the optimal modeling strategy. We invite you to contact us for complimentary technical consultation and personalized modeling recommendations based on your project needs.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
